Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CVDTEU

Financiado

Cerrado

Clinical validation of the DiviTum assay in key European markets

Many cancer therapies fail due to inadequate prediction of patient-specific treatment responses. In addition, a large number of clinical trials fail due to a lack of predictive tools for optimal cohort selection. Biovica has devel... ver más

28/02/2015

BIOVICA

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BIOVICA INTERNATIONAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-02-28

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BIOVICA

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIOVALID Clinical validation of the DiviTum assay in two high profile... 683K€ Cerrado

IOO - Improving IO IOO: a novel assay to predict patient response to immune che... 4M€ Cerrado

UNIBIO TK210 ELISA universal serum protein biomarker for cancer s... 71K€ Cerrado

BEAT B-cell Lymphoma BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assesse... Cerrado

ROUTINE canceR agnOstic immUnoTherapy predIctioN blood-tEst 4M€ Cerrado

MAINTRAC-Auto MAINTRAC Auto Automatization and validation of a liquid bio... 71K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2014-10-07
Fecha Fin: 2015-02-28

Líder del proyecto

BIOVICA INTERNATIONAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many cancer therapies fail due to inadequate prediction of patient-specific treatment responses. In addition, a large number of clinical trials fail due to a lack of predictive tools for optimal cohort selection. Biovica has developed a sensitive and precise assay for the measurement of a biomarker thymidine kinase (TK) from serum as an indicator of cell proliferation. Our assay technology has been clinically tested and has demonstrated beyond state-of-the-art capability compared to existing solutions due to its unprecedented sensitivity. This allows for previously unrealized capabilities in monitoring and prediction of therapy response for most common cancers. The unique selling point of our technology is the documented ability to reliably measure solid tumor proliferation from serum, thereby making it cheaper, more scalable and less invasive for the patient than industry standards. Our key customers are drug developers and clinicians who will use it for optimal cohort selection for clinical trials, and prediction of treatment response for patients respectively. However, in order to reach these customers, we require carrying out extensive clinical validations to demonstrate technological soundness. Europe represents the largest market for biomarker diagnostics due to a growing ageing population. We therefore aim to conduct clinical studies in key European markets with access to relevant bio-banks. In phase 1 of the proposed project, we will perform a feasibility study with focus on market related activities in Europe. Thereafter we aim to conduct clinical studies in selected European countries in partnership with clinicians. Our ambition is to become the industry standard for cancer proliferation measurement worldwide.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores